MX2021015946A - Receptores de linfocitos t de mage-a4 y métodos de uso de estos. - Google Patents
Receptores de linfocitos t de mage-a4 y métodos de uso de estos.Info
- Publication number
- MX2021015946A MX2021015946A MX2021015946A MX2021015946A MX2021015946A MX 2021015946 A MX2021015946 A MX 2021015946A MX 2021015946 A MX2021015946 A MX 2021015946A MX 2021015946 A MX2021015946 A MX 2021015946A MX 2021015946 A MX2021015946 A MX 2021015946A
- Authority
- MX
- Mexico
- Prior art keywords
- mage
- tcrs
- peptide
- antigen
- cell receptors
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 abstract 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962862726P | 2019-06-18 | 2019-06-18 | |
| US201962871793P | 2019-07-09 | 2019-07-09 | |
| PCT/US2020/038142 WO2020257288A2 (en) | 2019-06-18 | 2020-06-17 | Mage-a4 t cell receptors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015946A true MX2021015946A (es) | 2022-04-18 |
Family
ID=74040867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015946A MX2021015946A (es) | 2019-06-18 | 2020-06-17 | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220324939A1 (https=) |
| EP (1) | EP3986938A4 (https=) |
| JP (3) | JP7730765B2 (https=) |
| KR (1) | KR20220035387A (https=) |
| CN (2) | CN118994364A (https=) |
| AU (1) | AU2020295401A1 (https=) |
| BR (1) | BR112021025548A2 (https=) |
| CA (1) | CA3144253A1 (https=) |
| CL (2) | CL2021003366A1 (https=) |
| CO (1) | CO2022000281A2 (https=) |
| IL (1) | IL289042A (https=) |
| MA (1) | MA56548A (https=) |
| MX (1) | MX2021015946A (https=) |
| PH (1) | PH12021553152A1 (https=) |
| WO (1) | WO2020257288A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| SG11201901634UA (en) * | 2016-09-23 | 2019-04-29 | Lion Tcr Pte Ltd | An hbv antigen specific binding molecules and fragments thereof |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| PH12021553152A1 (en) * | 2019-06-18 | 2022-08-15 | Regeneron Pharma | Mage-a4 t cell receptors and methods of use thereof |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| TW202229327A (zh) * | 2020-10-02 | 2022-08-01 | 美國衛生與公眾服務部 | 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體 |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| EP4422651A4 (en) * | 2021-10-25 | 2025-12-17 | Univ Texas | PEPTIDES AND MANIPULATED T-CELL RECEPTORS FOR TARGETTING THE MAGE-A4 ANTIGEN AND METHOD FOR USE |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| WO2023238125A1 (en) * | 2022-06-08 | 2023-12-14 | Sheba Impact Ltd. | Virus-specific recombinant t cell receptors and t cells comprising them |
| JP2025525382A (ja) * | 2022-06-24 | 2025-08-05 | アムジエン・インコーポレーテツド | Ｍａｇｅａ４特異的ｔ細胞受容体 |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| JP2026509947A (ja) | 2022-10-31 | 2026-03-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法 |
| EP4393942A1 (en) * | 2022-12-29 | 2024-07-03 | Keshihua (Nanjing) Biotechnology Co., Ltd | Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr |
| AU2024214482A1 (en) | 2023-02-03 | 2025-08-07 | Zelluna Immunotherapy As | Anti-mage-a4 t cell receptors |
| CN119569851A (zh) * | 2023-09-05 | 2025-03-07 | 香雪生命科学技术（广东）有限公司 | 针对magea4的高亲和力tcr |
| WO2025233432A1 (en) * | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311914B2 (en) * | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| SMT202200306T1 (it) * | 2016-04-08 | 2022-09-14 | Immunocore Ltd | Recettori di cellule t |
| BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| DK3440106T3 (da) * | 2016-04-08 | 2021-10-04 | Adaptimmune Ltd | T-cellereceptorer |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| PH12021553152A1 (en) * | 2019-06-18 | 2022-08-15 | Regeneron Pharma | Mage-a4 t cell receptors and methods of use thereof |
-
2020
- 2020-06-17 PH PH1/2021/553152A patent/PH12021553152A1/en unknown
- 2020-06-17 JP JP2021575366A patent/JP7730765B2/ja active Active
- 2020-06-17 CA CA3144253A patent/CA3144253A1/en active Pending
- 2020-06-17 CN CN202411136604.9A patent/CN118994364A/zh active Pending
- 2020-06-17 MX MX2021015946A patent/MX2021015946A/es unknown
- 2020-06-17 KR KR1020227001750A patent/KR20220035387A/ko active Pending
- 2020-06-17 WO PCT/US2020/038142 patent/WO2020257288A2/en not_active Ceased
- 2020-06-17 AU AU2020295401A patent/AU2020295401A1/en active Pending
- 2020-06-17 EP EP20827786.3A patent/EP3986938A4/en active Pending
- 2020-06-17 US US17/618,973 patent/US20220324939A1/en active Pending
- 2020-06-17 MA MA056548A patent/MA56548A/fr unknown
- 2020-06-17 BR BR112021025548A patent/BR112021025548A2/pt unknown
- 2020-06-17 CN CN202080053852.0A patent/CN114585646B/zh active Active
-
2021
- 2021-12-15 CL CL2021003366A patent/CL2021003366A1/es unknown
- 2021-12-15 IL IL289042A patent/IL289042A/en unknown
-
2022
- 2022-01-17 CO CONC2022/0000281A patent/CO2022000281A2/es unknown
-
2024
- 2024-01-15 CL CL2024000119A patent/CL2024000119A1/es unknown
- 2024-08-13 JP JP2024135124A patent/JP2024164066A/ja active Pending
-
2025
- 2025-08-18 JP JP2025135733A patent/JP2025166209A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553152A1 (en) | 2022-08-15 |
| JP2024164066A (ja) | 2024-11-26 |
| KR20220035387A (ko) | 2022-03-22 |
| CN118994364A (zh) | 2024-11-22 |
| JP2022537359A (ja) | 2022-08-25 |
| CN114585646A (zh) | 2022-06-03 |
| JP7730765B2 (ja) | 2025-08-28 |
| WO2020257288A2 (en) | 2020-12-24 |
| BR112021025548A2 (pt) | 2022-05-17 |
| CA3144253A1 (en) | 2020-12-24 |
| US20220324939A1 (en) | 2022-10-13 |
| CN114585646B (zh) | 2024-09-03 |
| CL2021003366A1 (es) | 2022-08-19 |
| IL289042A (en) | 2022-02-01 |
| EP3986938A2 (en) | 2022-04-27 |
| MA56548A (fr) | 2022-04-27 |
| JP2025166209A (ja) | 2025-11-05 |
| AU2020295401A1 (en) | 2022-02-10 |
| WO2020257288A3 (en) | 2021-04-08 |
| EP3986938A4 (en) | 2023-06-28 |
| CO2022000281A2 (es) | 2022-01-28 |
| CL2024000119A1 (es) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015946A (es) | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. | |
| CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
| CY1124835T1 (el) | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας | |
| CY1125508T1 (el) | Υποδοχεις τ-κυτταρων ειδικων για το συμπλοκο καρκινικου αντιγονου ny-eso-1-hla-a 02 | |
| CY1125331T1 (el) | Υποδοχεις των τ κυτταρων | |
| SA519410362B1 (ar) | مستقبل للخلايا التائية (tcr) وببتيدات | |
| CY1124664T1 (el) | Υποδοχεις τ λεμφοκυτταρων | |
| CY1121962T1 (el) | Υποδοχεις τ κυτταρου | |
| CO2022011869A2 (es) | Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso | |
| CL2022003264A1 (es) | Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros | |
| PE20211058A1 (es) | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) | |
| WO2020086647A8 (en) | Ny-eso-1 t cell receptors and methods of use thereof | |
| MX2020010460A (es) | Receptores de células t, y células diseñadas que expresan los mismos. | |
| CL2022001305A1 (es) | Receptores de tcr de prame y usos de estos | |
| PE20191651A1 (es) | Anticuerpos agonistas anti-icos y sus usos | |
| CR20200287A (es) | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado | |
| MX2020010241A (es) | Composiciones de inmunoterapia celular y usos de las mismas. | |
| CR20180490A (es) | Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer | |
| EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| CO2018010808A2 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| FI3792628T3 (fi) | Menetelmiä neoantigeenien hyödyllisyyden ennustamiseen immunoterapiassa | |
| MX2022004906A (es) | Moleculas de union especifica. | |
| PE20191617A1 (es) | Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer | |
| MX2022007833A (es) | Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos. |